- Detailed Results Presented From ENLIGHTEN-Early Phase 3b Study of LYBALVI in Patients Early in Illness - DUBLIN, April 7, 2022 /PRNewswire/ Alkermes plc (Nasdaq: ALKS) today presented
- LYBALVI Demonstrated Less Weight Gain Compared to Olanzapine in Patients With Schizophrenia, Schizophreniform Disorder or Bipolar I Disorder - DUBLIN, Feb. 8, 2022 /PRNewswire/ Alkermes
- Respondents Reported Physical and Psychosocial Impacts of Living with Bipolar I Disorder and Side Effects of Medications Used to Treat the Disease - - More Than Half of Respondents Reported